Vascular Immunotargeting: Take the Highway to the First Exit
Vladimir R. Muzykantov, Jacob S. Brenner – 2 August 2018
Reply
Norah A. Terrault, Robert S. Brown, Anna SF Lok, John B Wong, Natalie H Bzowej, Kyong‐Mi Chang, Jessica P Hwang, Maureen M Jonas, Brian J McMahon – 2 August 2018
A New Concept: Pre‐HCC Disease
Yao Yang, Yuemin Feng, Xinya Zhao, Le Wang, Xiaoyu Xie, Jie Li, Mindie H. Nguyen, Qiang Zhu – 2 August 2018
Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases
Keith D. Lindor, Christopher L. Bowlus, James Boyer, Cynthia Levy, Marlyn Mayo – 2 August 2018
Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases
Keith D. Lindor, Christopher L. Bowlus, James Boyer, Cynthia Levy, Marlyn Mayo – 2 August 2018
The Efficacy of Tenofivir to Prevent Perinatal Transmission in Chronic Hepatitis BMothers. AClinical Perspective
Ghassan Mubarak, Richard Ferstenberg – 2 August 2018
Diabetes, Liver Cancer, and Cirrhosis: What Next?
Hannele Yki‐Järvinen, Panu K. Luukkonen – 2 August 2018
Mailed Outreach Invitations Significantly Improve HCC Surveillance Rates in Patients With Cirrhosis: A Randomized Clinical Trial
Amit G. Singal, Jasmin A. Tiro, Caitlin C. Murphy, Jorge A. Marrero, Katharine McCallister, Hannah Fullington, Caroline Mejias, Akbar K. Waljee, Wendy Pechero Bishop, Noel O. Santini, Ethan A. Halm – 2 August 2018 – Hepatocellular carcinoma (HCC) surveillance is associated with early tumor detection and improved survival in patients with cirrhosis; however, effectiveness is limited by underuse. We compared the effectiveness of mailed outreach and patient navigation strategies to increase HCC surveillance in a racially diverse cohort of patients with cirrhosis.
A Novel Mechanism of Starvation‐Stimulated Hepatic Autophagy: Calcium‐Induced O‐GlcNAc‐Dependent Signaling
Yang Shen, Mark J. Czaja – 2 August 2018
Plasma From Patients Undergoing Liver Transplantation Is Resistant to Anticoagulant Activity of Soluble Thrombomodulin
Laura C. Burlage, Sarah Bos, Jelle Adelmeijer, Takumi Sakai, Robert J. Porte, Ton Lisman – 1 August 2018 – Recombinant human soluble thrombomodulin (ART‐123) is an anticoagulant and anti‐inflammatory agent clinically used for treatment of disseminated intravascular coagulation. Preclinical studies have shown that ART‐123 reduces hepatic ischemia/reperfusion. Although ART‐123 may therefore have clinical benefit in orthotopic liver transplantation, the substantial alterations in the hemostatic system may complicate its use in this setting.